ELIXOMIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ELIXOMIN (ELIXOMIN).
ELIXOMIN binds to and inhibits the N-methyl-D-aspartate (NMDA) receptor, reducing excitatory neurotransmission. It also modulates gamma-aminobutyric acid (GABA) activity, enhancing inhibitory signaling.
| Metabolism | Primarily metabolized by CYP3A4 and CYP2C19 isoenzymes; undergoes glucuronidation via UGT1A4. Active metabolite: N-desethyl-ELIXOMIN. |
| Excretion | Renal elimination of unchanged drug accounts for 60-70% of clearance; biliary/fecal excretion accounts for 20-25%; the remainder is metabolized hepatically with inactive metabolites excreted renally. |
| Half-life | Terminal elimination half-life is 12-15 hours in adults with normal renal function; extends to 24-36 hours in moderate renal impairment (CrCl 30-50 mL/min). |
| Protein binding | 98% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.6-0.8 L/kg; distributes rapidly into total body water, with moderate tissue binding. |
| Bioavailability | Oral: 70-80% (due to first-pass metabolism); Intramuscular: 90-95%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes; Intramuscular: 10-20 minutes. |
| Duration of Action | Oral: 6-8 hours; Intravenous: 4-6 hours; Intramuscular: 4-6 hours. Duration may be prolonged in hepatic impairment due to reduced metabolic clearance. |
500 mg orally once daily with a full glass of water, regardless of meals.
| Dosage form | ELIXIR |
| Renal impairment | GFR > 60 mL/min: no adjustment; GFR 30-60 mL/min: 250 mg once daily; GFR 15-29 mL/min: 125 mg once daily; GFR < 15 mL/min or dialysis: not recommended. |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% (250 mg once daily); Class C: not recommended. |
| Pediatric use | Weight ≥ 40 kg: 500 mg once daily; Weight 20-39 kg: 250 mg once daily; Weight < 20 kg: not established. |
| Geriatric use | No specific dose adjustment except based on renal function. Monitor for increased risk of QT prolongation and electrolyte disturbances. Initial dose should be 250 mg once daily if CrCl < 60 mL/min. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ELIXOMIN (ELIXOMIN).
| Breastfeeding | Not recommended during breastfeeding. Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infant (e.g., nephrotoxicity, ototoxicity). |
| Teratogenic Risk | ELIXOMIN is contraindicated in pregnancy (Category X). First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies. Second and third trimesters: Increased risk of spontaneous abortion, preterm delivery, and fetal growth restriction due to uteroplacental insufficiency. |
■ FDA Black Box Warning
WARNING: Risk of suicidal thoughts and behaviors; monitor for worsening depression or emergence of suicidal ideation.
| Serious Effects |
Absolute: Hypersensitivity to ELIXOMIN or any component; history of drug-induced liver injury; concomitant use with MAOIs. Relative: Hepatic impairment; renal insufficiency (CrCl <30 mL/min); pregnancy (teratogenic effects in animal studies).
| Precautions | Hepatotoxicity (monitor LFTs); hematologic effects (thrombocytopenia, neutropenia); severe dermatologic reactions (SJS/TEN); pancreatitis; hyperammonemia; somnolence and dizziness; withdrawal seizures upon abrupt discontinuation. |
Loading safety data…
| Fetal Monitoring |
| Serial ultrasound for fetal growth and anatomy; nonstress test or biophysical profile in third trimester; maternal renal function (serum creatinine, BUN) and drug levels (trough/peak) weekly; audiometry for hearing impairment. |
| Fertility Effects | May impair fertility in females via ovarian toxicity (follicular depletion) and in males via testicular damage (azoo/oligospermia). Reversible upon discontinuation in some cases?. |